EXEL vs. SMMT: Exelixis vs. Summit Therapeutics Stock Comparison

November 11, 2026

How do Exelixis (EXEL) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Exelixis (EXEL) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Profile Item	EXEL	SMMT
Name	Exelixis Inc.	Summit Therapeutics Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	16.98 billion USD	13.06 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	April 17, 2000	March 5, 2015
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

EXEL

SMMT

GSPC

Exelixis (EXEL) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Exelixis (EXEL) and Summit Therapeutics (SMMT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Exelixis (EXEL) and Summit Therapeutics (SMMT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Metric	EXEL	SMMT
Total Return (1Y)	74.98%	-2.48%
Total Return (3Y, Annualized)	50.33%	116.18%
Total Return (5Y, Annualized)	31.10%	26.89%

Risk Profile

Drawdown History

EXEL

SMMT

GSPC

Exelixis (EXEL) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Exelixis (EXEL) and Summit Therapeutics (SMMT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Exelixis (EXEL) has a non-negative beta of 0.41.

Risk profile metrics for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Metric	EXEL	SMMT
Volatility (1Y, Annualized)	34.17%	75.06%
Beta (5Y)	0.41	-1.51
Max Drawdown (5Y)	-35.41%	-87.64%
Avg. Volume (3M)	2.33M	6.19M

Risk-Adjusted Performance

Risk-Return Positioning

EXEL and SMMT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Metric	EXEL	SMMT
Sharpe Ratio (1Y)	2.07	-0.09
Sortino Ratio (1Y)	3.23	-0.13

Profitability

ROE (TTM)

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Exelixis (EXEL) reports 44.32%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max: 109.18%
EXEL: 44.32%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

-220.01%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
SMMT: -220.01%

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Exelixis (EXEL) at 35.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL: 35.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
SMMT: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Exelixis (EXEL) at 40.75% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max: 83.12%
EXEL: 40.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
SMMT: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Metric	EXEL	SMMT
ROE (TTM)	44.32%	-220.01%
ROA (TTM)	23.52%	-111.99%
Net Margin (TTM)	35.45%	0.00%
Operating Margin (TTM)	40.75%	0.00%
Gross Margin (TTM)	96.26%	0.00%

Growth

Revenue Growth

Only one side can be read here: Exelixis (EXEL) reports revenue growth of 6.98%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Exelixis (EXEL) reports EPS growth of 57.95%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Metric	EXEL	SMMT
Revenue Growth (YoY)	6.98%	--
Revenue Growth (3Y CAGR)	12.93%	--
EPS Growth (YoY)	57.95%	--
EPS Growth (3Y CAGR)	70.59%	--

Financial Strength

Current Ratio (MRQ)

Both Exelixis (EXEL) at 3.21 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max: 25.13
Q3: 12.13
Median: 5.52
EXEL: 3.21
Q1: 2.47
Min: 0.10

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.99

Max: 25.13
Q3: 12.13
SMMT: 5.99
Median: 5.52
Q1: 2.47
Min: 0.10

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Exelixis (EXEL) at 0.09 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max: 1.42
Q3: 0.65
Median: 0.15
EXEL: 0.09
Q1: 0.02
Min: 0.00

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max: 1.42
Q3: 0.65
Median: 0.15
SMMT: 0.04
Q1: 0.02
Min: 0.00

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Metric	EXEL	SMMT
Current Ratio (MRQ)	3.21	5.99
Debt / Equity (MRQ)	0.09	0.04
Net Debt / EBITDA	-0.71	--

Dividends

Dividend Yield (TTM)

Neither Exelixis (EXEL) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Exelixis (EXEL) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Metric	EXEL	SMMT
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Exelixis (EXEL) trades at 20.83 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max: 85.34
Q3: 43.46
Median: 26.69
EXEL: 20.83
Q1: 13.30
Min: 0.07

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
SMMT: --

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): SMMT does not report P/E ratio, so it has no value marker; EXEL is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Exelixis (EXEL), whose P/S ratio of 6.80 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max: 58.18
Q3: 25.77
Median: 7.30
EXEL: 6.80
Q1: 3.01
Min: 0.01

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
SMMT: --

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): SMMT does not report P/S ratio, so it has no value marker; EXEL is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Both look rich against book: Exelixis (EXEL) at 9.28 sits in the upper P/B ratio quartile, and Summit Therapeutics (SMMT) at 23.13 prices even higher, above its industry range.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max: 13.53
EXEL: 9.28
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.13

SMMT: 23.13
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Exelixis (EXEL) vs. Summit Therapeutics (SMMT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Exelixis (EXEL) and Summit Therapeutics (SMMT)
Metric	EXEL	SMMT
P/E Ratio (TTM)	20.83	--
P/S Ratio (TTM)	6.80	--
P/B Ratio (MRQ)	9.28	23.13
Free Cash Flow Yield (TTM)	4.47%	-1.64%